MIRA Pharmaceuticals, Inc. (MIRA)
  • About Us
    • Overview
    • Board of Directors
    • Leadership
    • Scientific Advisory Board
  • Ketamir
    • Overview
    • Research & Publications
    • Pipeline
  • MIRA-55
    • Overview
    • Research & Publications
    • Pipeline
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • All SEC Filings
    • Governance
  • Contact
Select Page

18TH ANNUAL PAIN THERAPEUTICS SUMMIT

Oct 28 – Oct 29, 2024

Press Releases

Investor relations
  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quotes
    • Charts
    • Historic Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Results
    • Section 16 Filings
  • Governance
    • Overview
    • Board Committees
    • Governance Documents
Select Year:
Mon Jul 22, 2024 08:00 am

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

Mon Jul 15, 2024 07:00 am

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

Wed Aug 9, 2023 09:35 am

MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast

« Previous 1 2 3
  • Facebook logo
  • Twitter logo
  • Linkedin logo
  • Youtube logo

© 2024 MIRA Pharmaceuticals, Inc. All Rights Reserved.

  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Manage Cookie Preferences
  • Facebook
  • Instagram
  • Twitter
  • RSS
Disclaimer

You are about to review presentations, reports and/or filings of MIRA Pharmaceuticals, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. MIRA Pharmaceuticals, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by MIRA Pharmaceuticals, Inc.

I Accept I Decline

Corporate Governance

Reports Regarding LMP Automotive Holdings’ Accounting or Auditing Matters or Other Concerns and Communications with the Board of Directors.

Shareholders and interested parties may communicate directly with the Board of Directors, the Audit Committee of the Board of Directors with respect to accounting issues, questionable accounting or auditing matters or internal accounting controls, any other Board committee, any individual Director, any group of Directors or the Lead Independent Director by e-mailing businessethics@lmpah.com.

Reports may be made anonymously or confidentially.